Company Overview and News
While there has been a high level of excitement over the past few years with regard to CRISPR gene editing possibilities, some of the previously leading methods for effective genome manipulation and gene therapy have been lost in the mix. Sangamo Therapeutics (SGMO) has a strong proprietary product in their Zinc Finger Nuclease [ZFN] technology for genome modulation. They have recently generated significant buzz surrounding their widely successful quarter, and have laid a strong foundation moving forward. (52-0)
CRSP's update on their pipeline is encouraging - IND on track for 2017, first company in the CRISPR-Cas9 clinical space. (25-0)
Calyxt is using the excitement regarding cutting edge technologies in the genome editing space to support its product pipeline. (49-0)
Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Third Quarter 2017 Financial Results Conference Call. Participants are now in a listen-only mode. And later, we will open the lines for question. This call is recorded. A replay will be available later tonight on our website. (11-0)
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-1)
WASHINGTON, DC--(Marketwired - Oct 4, 2017) - The Alliance for Regenerative Medicine (ARM), announced today the election of its 2018 Executive Committee and Board of Directors. (39-2)
In a recent Financial Planning article, Craig Israelsen advocated using stock market size segments to construct portfolios rather than a total market approach. His conclusion may be perfectly valid for market participants willing and able to bear greater small-stock exposure, but his analysis fails to adequately take account of this source of risk. He compared returns of several index funds and reviewed results of combining them in a couple of different ways. (10-0)
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced today that Dr. Samarth Kulkarni, Ph.D., currently President of CRISPR Therapeutics, Inc., has been promoted to the role of Chief Executive Officer. Dr. Kulkarni will assume the role effective December 1, 2017. (12-0)
During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure. The ability to directly edit living cells has brought gene therapy and precision medicine into a new era, one that will accelerate the pace of scientific research and increase the value of molecular diagnostic tests. (25-1)
CRISPR Therapeutics is currently under appreciated considering they are the closest company to beginning clinical trials. (101-2)
September 15, 2017 - Versant Venture Capital IV, L.P. has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,752,256 shares of CRISPR Therapeutics AG (NASDAQ:CRSP). This represents 6.78 percent ownership of the company.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-3)
The European Patent Office (EPO) has told MilliporeSigma it intends to grant approval of its patent application covering the company's CRISPR technology used in a genomic integration method for eukaryotic cells—the second key patent awarded in Europe covering the gene-editing technology.
Some people reading this morning's mainstream press headlines about a Nature paper describing the correction of a germline mutation using Crispr (NASDAQ:CRSP) might be excused for thinking that we are entering a Gattaca-like world of designer babies.
* Crispr Therapeutics appoints Dr. Tony W. Ho to head research & development Source text for Eikon: Further company coverage:
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton